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ABSTRACT
Objective: The objective of the present research was to develop fixed-dose combinations for the treatment of dyslipidemia, associated with type-II 
diabetes mellitus for improvement of glucose tolerance.
Methods: Multiple unit pellet systems (MUPSs) consisting immediate release atorvastatin calcium pellets and sustained release glibenclamide were 
formulated by spheronization technique. The characterization of formulated pellets was done by Fourier transform infrared (FT-IR) and differential 
scanning calorimetry (DSC) studies, and formulated pellets were evaluated for solubility, viscosity, pH, and in vitro studies.
Results: From FT-IR and DSC studies, it was confirmed that no chemical interaction existed between the drug and the natural polymers used. Solubility 
of glibenclamide was found to be 4.38 and 18.24 and atorvastatin calcium was found to be 6.84, 214.67, and 287.43 g/L. The viscosity of 1% w/v of 
locust bean gum, guar gum, and ghatti gum was found to be 169 cP, 124 cP, and 31 cP in distilled water. The pH of locust bean gum, guar gum, and gum 
ghatti solutions was found to be 5.6±0.49, 5.2±0.27, and 4.7±0.51. The in vitro studies suggested that glibenclamide pellets had shown a sustained 
release till 12 h, while atorvastatin calcium had shown immediate release of drug due to rapid disintegration of pellets.
Conclusion: Thus, MUPS can be considered as an alternative approach to treat diabetes induced dyslipidemia.
Keywords: Multiple unit pellet system, Glibenclamide, Atorvastatin calcium, Sustained release, Immediate release.
INTRODUCTION
Diabetes mellitus is a heterogeneous group of disease characterized 
by elevation of glucose in the blood because of the impaired insulin 
secretions in body. Deficiency of insulin leads to chronic hyperglycemia 
with disturbances of carbohydrate, fat, and protein metabolism [1,2]. 
As the disease progresses, various tissues or vascular damage leads 
to many diabetic complications related to retinopathy, neuropathy, 
nephropathy, cardiovascular, and ulceration, thus diabetes covers a 
wide range of heterogeneous diseases. It is the most common endocrine 
disorder and estimated that more than 200 million people were 
suffering from diabetes [3]. Diabetes can be classified into two types, 
i.e., Type-I (insulin-dependent diabetes) and Type-II (non-insulin-
dependent diabetes). Patients suffering from Type-II diabetes will not 
respond effectively to insulin which can be termed as insulin resistance. 
When the blood glucose or sugar level is high, it can be termed as 
hyperglycemia, whereas when the blood glucose levels are lower than 
normal levels, it can be termed as hypoglycemia [4].
In recent times, among various drug delivery systems to treat diabetes 
induced dyslipidemia, multiple unit pellet systems (MUPSs) have 
grabbed attention of pharmaceutical industries, as they deliver both 
immediate and modified release drugs from as single system. The pellets 
that are present in this multiple unit can be coated or uncoated. When 
compared with other delivery techniques, these multiple unit pellet 
delivery systems possess advantages such as reduced toxicity, local 
irritation and dose dumping, and plasma concentration fluctuations, 
and it is able to administer high potency drugs [5].
Glyburide [6] is another name for glibenclamide, which comes under the 
class know as sulfonylureas; further, it is classified as either the second 
generation or the third generation of sulfonylureas. It is familiarly 
related as sulfonamide antibiotics, pharmaceutical preparation of 
glibenclamide is used only for Type-II diabetes and not for Type-I 
diabetes, because of insufficient production of insulin from pancreas. 
Glibenclamide acts by binding and inhibiting potassium channel (KATP) 
and sulfonylurea receptors in pancreatic beta-cell [7].
Atorvastatin comes under the family of statins; initially, it behaves as 
lipid-lowering agent and inhibits tasks associated with cardiovascular 
diseases. Atorvastatin plays a major role by inhibiting 3-hydroxy-3-
methylglutaryl-coenzyme A (HMG-CoA) reductase, an enzyme which is 
present in the liver tissue plays a key role in the production of cholesterol 
in the human body. The reduction of HMG-CoA to mevalonate is also 
catalyzed by HMG-CoA reductase [8].
Here, in the current research work, a basic pellet formulation 
consisting a drug and microcrystalline cellulose (MCC) was formulated 
by employing spheronization technique, to modify the drug release 
from various excipients which are taken in various proportions and 
combinations. The main objective of this formulation is to improve the 
glucose tolerance in Type-II diabetes.
MATERIALS AND METHODS
Materials
Glibenclamide was purchased from Sanket Pharmaceuticals Pvt., Ltd., Mumbai, 
and atorvastatin calcium API was purchased from Afton Pharma, Rajkot, 
Gujarat. All the other chemicals used in the study are of analytical grade.
Methods
Preparation of drug-loaded sustained release glibenclamide pellets
A uniform dry powder mixture (batch size 100 g) containing 
glibenclamide, MCC (Avicel PH 101), locust bean gum, and gum ghatti/
guar gum is taken in polyethylene bag in different concentrations 
as shown in Table 1. The above mixture was then granulated using 
© 2018 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
org/licenses/by/4. 0/) DOI: http://dx.doi.org/10.22159/ajpcr.2018.v11i12.26629
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water and isopropyl alcohol in 5:2 ratio as granulation fluid. Then, it is 
extruded, and the extrudates were then immediately spheronized to get 
the yield. The pellets were dried in hot air oven at 40°C for 10–12 h and 
stored in screw-capped, high-density polyethylene bottles [9].
Preparation of drug-loaded immediate release atorvastatin 
calcium pellets
Similar to above glibenclamide pellets formulation, uniform dry powder 
mixture (batch size 100 g) containing atorvastatin calcium and excipients 
such as MCC (Avicel PH 101), sodium starch glycolate/croscarmellose 
sodium, sodium lauryl sulfate (SLS), and sodium bicarbonate was taken 
in polyethylene bag as shown in Table 2. The mixture was then granulated 
using 1% w/w locust bean gum/PVP K-30 in water as granulation fluid. 
Then, the wet granulation mixture was extruded, and the extrudates were 
then immediately spheronized to yield the spherical pellets. The pellets were 
dried in hot air oven at 40°C for 10–12 h. After drying, pellets were then filled 
and stored in screw-capped, high-density polyethylene bottles [9].
Preformulation studies
The following preformulation studies were performed for glibenclamide 
and atorvastatin calcium pure drugs.
Fourier transform infrared (FT-IR) studies of glibenclamide and 
atorvastatin calcium
To determine compatibility of the drug and polymer, Fourier transform-
infrared (FT-IR) spectroscopy was done. Results were recorded using 
FT-IR (8400S, Shimadzu Corporation, Japan). API dispersed with KBr 
in mortar, the material is triturated into fine powder with the help of 
compression gauge the powder has been compressed in a holder, and 
pressure of 5 ton is applied for 5 min. The pellet was placed in the light 
path and results were recorded [10].
Differential scanning calorimetry (DSC)
DSC studies were carried out on Shimadzu thermal analyzer. A few 
milligrams of sample were hermetically sealed into aluminum pans and 
heated under nitrogen atmosphere with the heating rate of 10°C/min [11].
Solubility
Solubility studies of glibenclamide and atorvastatin calcium were 
carried out using distilled water. Glibenclamide and atorvastatin calcium 
were taken in vials containing distilled water. The vials were subjected 
to stirring for 24 h on a magnetic stirrer, and the obtained solution 
was filtered and the filtrate was estimated spectrophotometrically at 
wavelengths of 242 nm for glibenclamide and 246 nm for atorvastatin 
calcium, respectively [12].
pH of gums
The accurate measurement of pH was done using probe pH meter. 
Measurement was done by submerging the probe in the liquid until a 
reading is registered by the meter.
Micromeritic properties
Micromeritic properties for both glibenclamide and atorvastatin 
calcium such as angle of repose, Carr’s index, as well as tapped density 
were determined. The tapped density was determined using a tapped 
density tester in which the glass cylinder was tapped 100 times. To 
measure the tapped density, the process was continued until a constant 
value was attained. Angle of repose was the most widely used technique 
for measuring the flowability [by determining the shape of the powder 
heap]. The formula used to measure the flowability [13].
Scanning electron microscopic (SEM) studies
SEM was employed to investigate the surface morphology of the pellets 
which were prepared, before coating around the pellets during analysis. 
SEM was performed at 5 kV having different magnifications using 
Hitachi Noran System 7 manufactured by Thermo Fisher Scientific [14].
Evaluation of prepared pellets
Friability and pellet yield
Friability of pellets was determined by Roche friabilator. 10 g of pellets 
were subjected to testing at 25 rpm for 4 min. Samples were sieved and 
the pellets retained on the sieve were weighed, and percent friability 
Table 1: Formulation chart of sustained release glibenclamide pellets
Ingredient concentration (% w/w) Wetting agent volume
(Water: IPA) (5:2) (mL/g)Formulation Code Glibenclamide MCC Locust bean gum Gum ghatti Guar gum
BD-1 2.5 96.5 1 - - 0.80
BD-2 2.5 95.5 2 - - 0.77
BD-3 2.5 94.5 3 - - 0.77
BD-4 2.5 95.0 2 0.5 - 0.70
BD-5 2.5 94.5 2 1 - 0.77
BD-6 2.5 94.0 2 1.5 - 0.84
BD-7 2.5 93.5 2 2 - 0.84
BD-8 2.5 93.0 2 2.5 - 0.80
BD-9 2.5 95.0 2 - 0.5 0.74
BD-10 2.5 94.5 2 - 1 0.74
Table 2: Formulation chart of immediate release atorvastatin calcium pellets
Ingredient concentration (% w/w)
Formulation Atorvastatin calcium MCC SSG CCS Sodium bicarbonate SLS
FR-1 4 92 1 - 2 1
FR-2 4 91 2 - 2 1
FR-3 4 90 3 - 2 1
FR-4 4 89 4 - 2 1
FR-5 4 88 5 - 2 1
FR-6 4 87 6 - 2 1
FR-7 4 86 7 - 2 1
FR-8 4 92 - 1 2 1
FR-9 4 91 - 2 2 1
FR-10 4 90 - 3 2 1
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was calculated from the difference in the weight of the pellets before 
and after friability.
Drug loading and encapsulation efficiency
To the freshly prepared 100 ml phosphate buffer of pH 6.8 with 0.5% 
w/v SLS, a specific amount of crushed pellets were suspended with 
constant agitation at room temperature for 24h. The final solution was 
filtered via Whatman filter paper, and drug content was determined 
separately for each pellet formulation by spectrophotometric method 
at the specific wavelengths.
Pellets disintegration time
Special transparent tubes having the diameter of 10-mm and 15-mm 
length were employed in pellet disintegration tester. The sieves of 710-
mm mesh size were at bottom and as well as top of the tubes. 100 mg of 
pellets is filled in the tubes and they were placed in the standard tablet 
disintegration tester. The disintegration time of six dried samples at 37°C 
was determined at a speed of 30 dips. Disintegration test was carried out 
3 times for each formulation, and results were expressed [14].
In vitro dissolution studies
Electrolab USP dissolution testing apparatus I (basket type) was used to 
evaluate the rate of drug release from formulated pellets. A weighed quantity 
equivalent to 100 mg of pellets was taken in 500 mL of 7.4 pH phosphate 
buffer. The test was carried out for 12 h at 37±1°C and 100 rpm. 2 mL of 
sample was withdrawn at preset time intervals and replaced with equal 
volume of dissolution medium. Withdrawn sample was filtered and 
analyzed spectrophotometrically at wavelength of 242 nm and 246 nm [14].
RESULTS AND DISCUSSION
Solubility
Solubility of glibenclamide was found to be 4.38, 18.24, and 24.09 g/L in 
pH 1.2, 6.8, and 7.2. Similarly, the solubility of atorvastatin calcium was found 
to be 6.84, 214.67, and 287.43 g/L in pH 1.2, 6.8, and 7.2 phosphate buffers, 
respectively. From the results, it can be inferred that both glibenclamide and 
atorvastatin calcium were more soluble in alkaline pH, i.e.,>7.
pH of gums
The locust bean gum is a non-ionic neutral polysaccharide and it reduces 
syneresis at a pH range of 5.6±0.49, guar gum had shown results to treat 
diabetes, and pH of guar gum obtained was 5.2±0.27. Ghatti gum having 
a pH range of 4.7±0.51 was favorable for formulation of pellets.
Characterization of sustained release glibenclamide pellets
FT-IR studies of glibenclamide
The position of peak in FT-IR spectra of pure glibenclamide is compared 
with those in FT-IR spectra of glibenclamide with excipients as shown 
in Fig. 1. FT-IR spectral analysis indicates that the characteristic 
absorption peaks present in the IR spectra of glibenclamide drug were 
also found in the physical mixtures of the polymers used (locust bean 
Fig. 1: Fourier transform infrared spectra of (a) glibenclamide pure drug, (b) glibenclamide + locust bean gum, (c) glibenclamide + gum 
ghatti; (d) glibenclamide + guar gum; (e) glibenclamide + MCC
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gum/gum ghatti/guar gum/MCC) without any appreciable change in 
the position, attributing to the compatibility of drug-polymer. Hence, it 
can be inferred that drug can be used with the selected polymer without 
causing any instability in the formulation.
FT-IR studies of atorvastatin calcium
The position of peak in FT-IR spectra of pure atorvastatin calcium is 
compared with those in FT-IR spectra of atorvastatin calcium with 
excipients as shown in Fig. 2. FT-IR spectral analysis indicates that 
the absorption peaks present in the IR spectra of atorvastatin calcium 
were also found in the physical mixtures of the excipients used (MCC/
locust bean gum/sodium starch glycolate/croscarmellose sodium/
SLS/sodium bicarbonate/PVP K-30) without any appreciable change 
in the position, attributing to the compatibility of drug-polymer. From 
the obtained results, it can be inferred that drug can be used with the 
selected polymer without causing instability in the formulation.
DSC studies of glibenclamide
From Fig. 3, it was evident that glibenclamide showing a sharp endothermic 
peak at its melting point, i.e., at 213.83°C, indicating its crystalline nature 
of the drug. On the other hand, the DSC thermographs of formulation BD-
2, BD-8, and BD-13 showed identical peaks, to that of pure drug indicating 
the absence of chemical interaction between the drug and polymers.
DSC studies of atorvastatin calcium pellets
The thermal analysis of pure atorvastatin calcium API showed a sharp 
endothermic peak at its melting point, i.e., at 156.87°C, demonstrating 
its crystalline nature. On the other hand identical, but broad peaks 
were found on DSC analysis of formulations FR-7, FR-14, and FR-15, 
indicating no interaction of atorvastatin calcium with its polymers and 
excipients. DSC thermograms of atorvastatin calcium API, formulation 
FR-7, FR-14, and FR-15 are presented in below Fig. 4.
Fig. 2: Fourier transform infrared spectra of (a) atorvastatin calcium pure drug, (b) atorvastatin calcium + microcrystalline cellulose; 
(c) atorvastatin calcium + sodium starch glycolate; (d) atorvastatin calcium + croscarmellose sodium; (e) atorvastatin calcium + sodium 
lauryl sulfate; (f) atorvastatin calcium + locust bean gum; (g) atorvastatin calcium + sodium bicarbonate; (h) atorvastatin calcium + PVP K-30
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Micromeritic properties of glibenclamide
The micromeritic properties of different batches of sustained release 
glibenclamide pellets are summarized in Table 3. The properties such 
as average size (mm), angle of repose, Carr’s index, and tapped density 
explain that no respective change differences among all batches. Angle 
of repose having a range of 23.20±1.35–27.35±1.58° which indicates 
good flow properties of pellets. The bulk density results of different 
batches of sustained release glibenclamide pellets indicated closely 
packed and settled nature because of narrow particle size distribution.
Micromeritic properties of atorvastatin calcium
The micromeritic properties of different batches of immediate release 
atorvastatin calcium pellets are summarized in below Table 4. The 
properties such as average size (mm), angle of repose, Carr’s index, 
and tapped density did not show any significant differences among 
the batches. Angle of repose was found to be within the range of 
24.19±1.33−27.21±1.69° indicating good flow properties of pellets.
SEM studies of glibenclamide pellets
From the SEM photographs (Fig. 5), it was observed that the sustained 
release glibenclamide pellets formulated using locust bean gum and 
gum ghatti/guar gum polymers exhibited spherical shape. The pellets 
consisting of locust bean gum alone and locust bean gum with gum 
ghatti polymer were of smoother surface, while pellets prepared using 
guar gum along with locust bean gum showed chapped surface.
SEM studies of atorvastatin calcium pellets
From the SEM photographs (Fig. 6), it was observed that the immediate 
release atorvastatin calcium pellets formulated using 1% w/w locust 
bean gum as binder and sodium starch glycolate/croscarmellose 
sodium exhibited spherical shape. The pellets consisting of locust 
bean gum and sodium starch glycolate were of smoother surface, while 
pellets prepared using locust bean gum and croscarmellose sodium 
showed chapped surface.
Evaluation of glibenclamide pellets and atorvastatin calcium pellets
Friability and pellet yield of glibenclamide
The results of friability test and pellet yield of the sustained release 
glibenclamide pellet formulations were summarized. The friability of 
the sustained release glibenclamide pellet formulations was found to 
be in the range of 0.32±0.08–0.53±0.07% results were in acceptable 
limits. The pellet yield was in the range of 76.9±2.31–83.3±3.16% in 
successive unit operations when 100 g of bulk material is being used.
Friability and pellet yield of atorvastatin calcium
The results of friability test and pellet yield of the immediate 
release atorvastatin calcium pellet formulations were summarized. 
The friability of the immediate release atorvastatin calcium pellet 
formulations was found to be in the range of 0.44±0.02–0.54±0.05% 
results were in acceptable limits. The pellet yield was in the range of 
Table 3: Characteristics of sustained release glibenclamide pellets formulation
Formulation 
code






BD-1 1135±51 25.14±1.24 1.05±0.03 0.84±0.04 9.12±0.32
BD-2 1189±25 26.42±1.18 1.03±0.04 0.86±0.07 8.79±0.24
BD-3 1245±23 25.45±1.26 1.08±0.03 0.90±0.03 9.39±0.21
BD-4 1224±35 23.20±1.35 1.05±0.02 0.89±0.06 8.93±0.34
BD-5 1318±27 27.21±1.30 1.12±0.06 0.83±0.05 8.76±0.30
BD-6 1336±32 26.48±1.44 1.04±0.08 0.83±0.05 8.69±0.37
BD-7 1361±37 25.16±1.15 1.06±0.07 0.84±0.07 8.85±0.24
BD-8 1380±21 26.65±1.88 1.09±0.05 0.90±0.03 9.39±0.36
BD-9 1262±73 26.83±1.28 1.08±0.06 0.89±0.04 8.93±0.29
BD-10 1294±42 26.25±1.36 1.16±0.04 0.83±0.05 8.76±0.38
*Standard deviation n=3
Table 4: Characteristics of immediate release atorvastatin calcium pellet formulations






FR-1 1127±41 25.14±1.52 1.09±0.04 0.79±0.05 8.11±0.42
FR2 1177±30 26.42±1.24 1.04±0.02 0.81±0.04 8.19±0.49
FR-3 1255±43 25.25±1.46 1.07±0.08 0.80±0.05 9.21±0.44
FR-4 1274±45 24.19±1.33 1.03±0.06 0.75±0.05 8.01±0.18
FR-5 1371±50 27.21±1.69 1.05±0.04 0.76±0.04 8.24±0.80
FR-6 1204±57 26.18±1.27 1.05±0.06 0.83±0.03 9.09±0.41
FR-7 1140±27 25.06±1.29 1.08±0.03 0.80±0.05 8.21±0.61
FR-8 1208±32 26.65±1.47 1.06±0.05 0.84±0.02 8.54±0.54
FR-9 1219±44 26.55±1.24 1.02±0.04 0.81±0.04 8.05±0.87
FR-10 1244±37 26.04±1.35 1.07±0.06 0.85±0.05 8.46±1.03
*Standard deviation n=3
Fig. 3: Differential scanning calorimetry thermogram of 
glibenclamide API, formulation BD-2, BD-8, and BD-13
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74.8±1.21–82.4±1.49% in successive unit operations when 100 g of 
bulk material is being used.
Drug loading and encapsulation efficiency glibenclamide
Percentage of drug loaded and percentage of drug encapsulated were 
found to be within the ranges of 2.28±0.23–2.55±0.15% and 85.40±1.21–
95.51±1.23%. Results suggested that as the concentration of polymer 
increased there was an increase in drug loading and encapsulation 
efficiency. Thus, from the results, it can be inferred that glibenclamide 
was distributed uniformly in the pellets with acceptable deviations.
Drug loading and encapsulation efficiency of atorvastatin 
calcium pellets
Percentage of drug loaded and percentage of drug encapsulated 
were found to be within the ranges of 3.06±0.18–3.80±0.31% and 
87.15±0.96–95.19±1.76%. Thus, from the results, it can be inferred 
that atorvastatin calcium was distributed uniformly in the pellets with 
acceptable deviations.
Pellets disintegration time atorvastatin calcium
Atorvastatin calcium pellets formulated using sodium starch glycolate 
as superdisintegrant had shown high disintegration when compared 
to croscarmellose sodium. As depicted in Fig. 7, results suggested that 
higher disintegration time is due to swelling of pellets when it comes to 
contact with aqueous medium and forming a gel, forming pores in the 
pellets prolonging the disintegration. While pellets formulated by using 
croscarmellose had shown enhanced disintegration by rapid swelling 
caused by capillary action.
In vitro dissolution studies
The sustained release glibenclamide and immediate release atorvastatin 
calcium pellets were mixed together in fixed-dose combination (FDC) 
and filled in a single hard gelatin capsule and evaluated for in vitro drug 
release study. As depicted in Figs. 8a-c and 9a and b, results suggested 
that as the concentration of polymer increases in glibenclamide pellets 
leaded to a significant decrease in dissolution of drug up to 12 h. While 
for atorvastatin calcium pellets, containing superdisintegrant had 
shown the complete release of drug within 45 min.
CONCLUSION
There is a strong prophylactic and clinical need to develop novel 
fixed combination delivery systems for the patients suffering from 
dyslipidemia in type-II diabetes mellitus for improvement of glucose 
tolerance with desired characteristics such as better therapeutic efficacy, 
convenience, reduced pill burden, and simplified administration of 
regimens with cost-effective medication. The developed FDC dosage 
forms, namely MUPSs, have demonstrated their superiority in both 
retarding the drug release of glibenclamide and immediate release of 
atorvastatin calcium. Thus, the study demonstrates that the developed 
FDC systems have a great appeal for the convenient treatment of 
Fig. 4: Differential scanning calorimetry thermogram of 
atorvastatin calcium API, formulation FR-7, FR-14, and FR-15
Fig. 7: Disintegration time of different formulations of immediate 
release atorvastatin calcium pellets
Fig. 6: Scanning electron microscopic of immediate release 
atorvastatin calcium pellets: (a) formulation FR-7 and 





Fig. 5: Scanning electron microscopic of sustained release 
glibenclamide pellets: (a) formulation BD-2, (b) formulation 
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diabetic dyslipidemia that may be explored in improving the limitations 
of existing monotherapy drug delivery systems.
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